Khiron Life Sciences Competitors

Abacus Health Products (OTCMKTS:ABAHF) and Khiron Life Sciences (OTCMKTS:KHRNF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Abacus Health Products and Khiron Life Sciences, as provided by MarketBeat.

Khiron Life Sciences has a consensus target price of $2.80, indicating a potential upside of 522.22%. Given Khiron Life Sciences' higher probable upside, analysts plainly believe Khiron Life Sciences is more favorable than Abacus Health Products.

Earnings and Valuation

This table compares Abacus Health Products and Khiron Life Sciences' gross revenue, earnings per share and valuation.

Profitability

This table compares Abacus Health Products and Khiron Life Sciences' net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Acreage, as provided by MarketBeat.com.

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Acreage has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Khiron Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Acreage.

Valuation and Earnings

This table compares Khiron Life Sciences and Acreage's gross revenue, earnings per share and valuation.

Profitability

This table compares Khiron Life Sciences and Acreage's net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats Acreage on 2 of the 3 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Applied Biosciences, as provided by MarketBeat.com.

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Given Khiron Life Sciences' higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Applied Biosciences.

Valuation and Earnings

This table compares Khiron Life Sciences and Applied Biosciences' gross revenue, earnings per share and valuation.

Profitability

This table compares Khiron Life Sciences and Applied Biosciences' net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Ayr Strategies, as provided by MarketBeat.com.

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Ayr Strategies has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Khiron Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Ayr Strategies.

Valuation and Earnings

This table compares Khiron Life Sciences and Ayr Strategies' gross revenue, earnings per share and valuation.

Profitability

This table compares Khiron Life Sciences and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats Ayr Strategies on 2 of the 3 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Can B, as provided by MarketBeat.com.

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Given Khiron Life Sciences' higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Can B.

Valuation and Earnings

This table compares Khiron Life Sciences and Can B's gross revenue, earnings per share and valuation.

Profitability

This table compares Khiron Life Sciences and Can B's net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats Can B on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Cansortium, as provided by MarketBeat.com.

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Cansortium has a consensus target price of $1.20, indicating a potential upside of 41.18%. Given Khiron Life Sciences' higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Cansortium.

Valuation and Earnings

This table compares Khiron Life Sciences and Cansortium's gross revenue, earnings per share and valuation.

Profitability

This table compares Khiron Life Sciences and Cansortium's net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats Cansortium on 1 of the 1 factors compared between the two stocks.